Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Semnur Pharmaceuticals, Inc. incurred convertible notes of up to $825,000 with Denali Capital Global Investments LLC at interest equivalent to the lowest short-term Applicable Federal Rate maturing upon the earlier of (i) the closing of Denali's initial business combination and (ii) the date of the liquidation of Denali.
- Instrument
- convertible notes
- Principal
- up to $825,000
- Counterparty
- Denali Capital Global Investments LLC
- Rate
- interest equivalent to the lowest short-term Applicable Federal Rate
- Maturity
- upon the earlier of (i) the closing of Denali's initial business combination and (ii) the date of the liquidation of Denali
- Event
- incurrence
Exact text from the filing
On April 11, 2023, Denali issued a convertible promissory note (the "Convertible Promissory Note") in the total principal amount of up to $825,000 to the Sponsor.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Semnur Pharmaceuticals, Inc. amended Amendment to and Consent under the Merger Agreement with Denali Capital Acquisition Corp., Longevity Biomedical, Inc., Denali SPAC Holdco, Inc., Denali SPAC Merger Sub, Inc., Longevity Merger Sub, Inc., Bradford A. Zakes, and Denali Capital Global Investments LLC (effective 2023-04-11).
- Action
- amendment
- Agreement
- merger
- Counterparty
- Denali Capital Acquisition Corp., Longevity Biomedical, Inc., Denali SPAC Holdco, Inc., Denali SPAC Merger Sub, Inc., Longevity Merger Sub, Inc., Bradford A. Zakes, and Denali Capital Global Investments LLC
- Effective
- 2023-04-11
Exact text from the filing
On April 11, 2023, the parties to the Merger Agreement and Denali Capital Global Investments LLC, a Cayman Islands limited liability company (the “Sponsor”) entered into an Amendment to and Consent under the Merger Agreement (the “Amendment”).
View on SEC.gov